Navigation Links
GEN point of view article questions reported costs of drug R&D
Date:7/6/2011

New Rochelle, NY, July 6, 2011A policy specialist and a healthcare economist both say that the oft-quoted cost of $1.32 billion to bring a new drug to market does not hold up to close scrutiny, reports Genetic Engineering & Biotechnology News (GEN). The researchers emphasize that available cost data cannot be trusted because the numbers are subject to numerous internal and external sources of variability, according to the July issue of GEN (http://www.genengnews.com/gen-articles/drug-r-d-costs-questioned/3707).

"With heated discussions still taking place over healthcare reform and a regulatory environment increasingly focused on safety, the GEN point of view piece should serve as an important article for multiple discussions on new drug R&D and commercialization costs," says John Sterling, Editor in Chief of GEN. "We hope that the article leads to an informative debate on this crucial issue of new drug research and development costs."

Donald W. Light, Ph.D., a professor at the University of Medicine and Dentistry of New Jersey and the Lokey visiting professor in human biology at Stanford University, and Rebecca Warburton, Ph.D., an associate professor at the University of Victoria (British Columbia), claim that pharmaceutical firms list their R&D costs as high as possible to garner greater prices for their products. Yet, continue the article's authors, a number of independent review groups report that 85% of new drugs exhibit few if any advantages over existing drugs.

Noting that the "R" in R&D is basically unknown and highly variable, Drs. Light and Warburton estimate that the median development ("D") cost for a new drug in 2000 was about $60 million (ranging from $13 million to $203 million depending on the type of drug) while the median D cost in 2006 was approximately $98 million (ranging from $21 million to $333 million).

For a copy of the July issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com

Genetic Engineering & Biotechnology News (GEN, www.genengnews.com) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, such as news and analysis, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. Yale researchers pinpoint reasons for dramatic rise in cesarean births
2. Anaphore Appoints Paul A. Grayson President and CEO
3. Salk scientist Joseph Ecker, appointed as HHMI-GBMF Investigator
4. CSHL professor Rob Martienssen receives prestigious appointment as HHMI-GBMF investigator
5. TGen Drug Development partners with Imaging Endpoints for comprehensive clinical trial services
6. Scientists use super microscope to pinpoint body’s immunity switch
7. Rices origins point to China, genome researchers conclude
8. Human rules may determine environmental tipping points
9. Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer
10. Viral replicase points to potential cancer therapy
11. ID Analytics Strengthens Management Team With Appointment of Senior Executives
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GEN point of view article questions reported costs of drug R&D
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):
(Date:9/21/2017)... ... September 21, 2017 , ... Colpitts Clinical has ... the portal includes new features that facilitate streamlined and compliant communication, file sharing ... at the forefront of medical advancements, they rely on efficiencies to help them ...
(Date:9/21/2017)... ... 2017 , ... When a downtown Greenville portion of the ... efficient thanks to the continuing efforts of members of the Reedy River Water ... stakeholders, including officials from area counties and cities, Renewable Water Resources (ReWa), community ...
(Date:9/20/2017)... ... ... The award-winning producers behind the American Farmer series proudly ... at helping farmers solve the problem of nitrogen loss. The upcoming episode is ... RFD-TV. Check your local listings for more info. , As a global ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... provider of engineering, architecture, project controls, construction management, commissioning and qualification services, ... the unveiling of the iCON™ brand which represents the collective facility design ...
Breaking Biology Technology: